Marijuana Misadventures in Children: Exploration of a Dose-Response Relationship and Summary of Clinical Effects and Outcomes.
Justin W Heizer, Laura M Borgelt, Ferras Bashqoy, George S Wang, Pamela D Reiter
Pediatric Emergency Care July 2018 DOI: 10.1097/pec.0000000000000770 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Retrospective review Peer reviewed |
|---|---|
| Sample size | 76 |
| Population | Children aged 31 days to 20 years presenting to Children's Hospital Colorado for care related to acute THC toxicity; 38 THC-naïve and 38 THC non-naïve children |
| Topics | Cannabis |
| Key findings | Among eight THC-naïve children with estimated oral doses, the authors observed a direct relationship between estimated THC dose (mg/kg), level of medical intervention required, and hospital disposition. Lethargy/somnolence was more common in naïve children (84% vs 26%), while cognitive, perceptual, and behavioral problems were more common in non-naïve children (11% vs 4%); duration of clinical effect (19.3 vs 5.0 hours) and hospital stay (0.73 vs 0.19 days) were longer in the naïve group. |
Abstract
This study aimed to explore a dose-response relationship of delta-9-tetrahydrocannabinol (THC) in THC-naïve children after unintentional acute exposure and compare clinical outcomes with non-naïve children. A retrospective review was performed on children aged 31 days to 20 years who presented to Children's Hospital Colorado for care related to acute THC toxicity. The children were divided into groups based on exposure: group 1 (THC naïve) and group 2 (THC non-naïve). A total of 38 children (age, 3.5 [3] years) met inclusion for group 1 and an equal number of children (age, 15.1 [3.9] years) met the criteria for comparison in group 2. Eight naïve patients had documentation of estimated THC dose ingested (mean [SD], 7.13 [5.8] mg/kg; range, 2.9-19.5 mg/kg). A direct relationship between estimated oral THC dose, level of medical intervention required, and hospital disposition was observed. Lethargy/somnolence was more common in the naïve group (84% vs. 26%, P < 0.0001) whereas problems in cognition, perception, and behavior were more common in the non-naïve group (4% vs 11%, P = 0.01). The duration of clinical effect and length of hospital stay were longer in the naïve group (19.3 vs 5.0 hours, P < 0.0001) and (0.73 vs 0.19 days, P < 0.0001) respectively. There seems to be a direct relationship between the estimated oral THC dose (mg/kg), hospital disposition, and level of medical intervention required. Symptoms and duration of effects after THC exposure varied based on the route of exposure, age of patient, and history of previous THC experience.
Comparable studies
Other observational and cohort studies on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population | 2009 | Case-control study | n = 454 |
| Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population | 2013 | Observational study | |
| Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people | 2000 | Observational | |
| Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline | 2011 | Observational cohort | n = 1,923 |
| Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... | 2005 | Observational cohort | n = 535 |
Citations in the library
Cites 2
- Biomarkers for the effects of cannabis and THC in healthy volunteers. British Journal of Clinical Pharmacology January 2009
- Modelling of the concentration--effect relationship of THC on central nervous system parameters and heart rate -- insight into its mechanisms of action and a tool for clinical research and development of cannabinoids. Journal of Psychopharmacology September 2008